Oppenheimer Asset Management Inc. Lowers Stock Holdings in Smith & Nephew SNATS, Inc. $SNN

Oppenheimer Asset Management Inc. lowered its position in Smith & Nephew SNATS, Inc. (NYSE:SNN) by 28.2% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 45,440 shares of the medical equipment provider’s stock after selling 17,874 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Smith & Nephew SNATS were worth $1,649,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Royal Bank of Canada lifted its position in shares of Smith & Nephew SNATS by 16.7% in the first quarter. Royal Bank of Canada now owns 340,428 shares of the medical equipment provider’s stock valued at $9,657,000 after acquiring an additional 48,784 shares in the last quarter. Goldman Sachs Group Inc. grew its position in shares of Smith & Nephew SNATS by 49.2% during the first quarter. Goldman Sachs Group Inc. now owns 1,771,401 shares of the medical equipment provider’s stock worth $50,255,000 after purchasing an additional 583,809 shares in the last quarter. Focus Partners Wealth raised its stake in Smith & Nephew SNATS by 59.8% during the 1st quarter. Focus Partners Wealth now owns 19,438 shares of the medical equipment provider’s stock valued at $552,000 after purchasing an additional 7,277 shares during the period. Callan Family Office LLC purchased a new position in Smith & Nephew SNATS in the 2nd quarter worth approximately $250,000. Finally, Inspire Investing LLC purchased a new position in Smith & Nephew SNATS in the 2nd quarter worth approximately $223,000. 25.64% of the stock is owned by institutional investors.

Analyst Ratings Changes

SNN has been the subject of a number of research analyst reports. Kepler Capital Markets raised shares of Smith & Nephew SNATS to a “strong-buy” rating in a report on Monday, November 17th. Weiss Ratings restated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research report on Wednesday, January 21st. Wall Street Zen raised shares of Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 10th. Canaccord Genuity Group reduced their price target on shares of Smith & Nephew SNATS from $36.00 to $34.00 and set a “hold” rating on the stock in a report on Tuesday, November 11th. Finally, Royal Bank Of Canada cut shares of Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a research note on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $35.75.

Smith & Nephew SNATS Stock Performance

Smith & Nephew SNATS stock opened at $36.16 on Friday. Smith & Nephew SNATS, Inc. has a 52-week low of $23.91 and a 52-week high of $38.79. The company has a quick ratio of 1.40, a current ratio of 3.00 and a debt-to-equity ratio of 0.60. The firm’s fifty day moving average is $33.48 and its 200 day moving average is $34.77.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.